Retraction: Prostate cancer cell lines under hypoxia exhibit greater stem-like properties (PLoS ONE (2011) 6: 12 (e29170) DOI: 10.1371/journal.pone.0029170);Prostate cancer cell lines under hypoxia exhibit greater stem-like properties

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Ma, Yuanyuan ^a,b   Liang, Dongming ^a   Liu, Jian ^a   Axcrona, Karol ^a   Kvalheim, Gunnar ^a   Stokke, Trond ^a   Nesland, Jahn M ^a,b   Suo, Zhenhe ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; PRIMER DNA;

ARTICLE; CANCER CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL HYPOXIA; COLONY FORMATION; CONTROLLED STUDY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; NANOG GENE; NANOGP8 GENE; OXYGEN TENSION; PROSTATE CANCER; PROTEIN EXPRESSION; SIDE POPULATION CELL; STEM CELL; UPREGULATION; CANCER STEM CELL; GENE EXPRESSION PROFILING; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOPHENOTYPING; MALE; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

BASE SEQUENCE; CELL HYPOXIA; CELL LINE, TUMOR; DNA PRIMERS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84555203275     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0233203     Document Type: Erratum

References (56)

1. Crea F, Mathews LA, Farrar WL, Hurt EM, (2009) Targeting prostate cancer stem cells. Anticancer Agents Med Chem 9: 1105-13.
2. Maitland NJ, Collins AT, (2008) Prostate cancer stem cells: a new target for therapy. J Clin Oncol 26: 2862-70.
3. Marignol L, Coffey M, Lawler M, Hollywood D, (2008) Hypoxia in prostate cancer: a powerful shield against tumour destruction? Cancer Treat Rev 34: 313-27.
4. Sharifi N, Kawasaki BT, Hurt EM, Farrar WL, (2006) Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy. Cancer Biol Ther 5: 901-6.
5. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, et al. (2010) Hypoxia inducible factors in cancer stem cells. Br J Cancer 102: 789-95.
6. Bae KM, Su Z, Frye C, Mcclellan S, Allan RW, et al. (2010) Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol 183: 2045-53.
7. Chen C, Wei Y, Hummel M, Hoffmann TK, Gross M, et al. (2011) Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS One 6: e16466.
8. Nirasawa S, Kobayashi D, Tsuji N, Kuribayashi K, Watanabe N, (2009) Diagnostic relevance of overexpressed Nanog gene in early lung cancers. Oncol Rep 22: 587-91.
9. Peng S, Maihle NJ, Huang Y, (2010) Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene 29: 2153-9.
10. Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, et al. (2009) Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 16: 3488-98.
11. Sotomayor P, Godoy A, Smith GJ, Huss WJ, (2009) Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. Prostate 69: 401-10.
12. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507.
13. Sperger JM, Chen X, Draper JS, Antosiewicz JE, Chon CH, et al. (2003) Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. Proc Natl Acad Sci U S A 100: 13350-5.
14. Ambady S, Malcuit C, Kashpur O, Kole D, Holmes WF, et al. (2010) Expression of NANOG and NANOGP8 in a variety of undifferentiated and differentiated human cells. Int J Dev Biol 54: 1743-54.
15. Zhang J, Wang X, Li M, Han J, Chen B, et al. (2006) NANOGP8 is a retrogene expressed in cancers. Febs J 273: 1723-30.
16. Jeter CR, Badeaux M, Choy G, Chandra D, Patrawala L, et al. (2009) Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 27: 993-1005.
17. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ, (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-51.
18. Miki J, Furusato B, Li H, Gu Y, Takahashi H, et al. (2007) Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 67: 3153-61.
19. Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, et al. (2009) Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate 69: 787-98.
20. Bhatt RI, Brown MD, Hart CA, Gilmore P, Ramani VA, et al. (2003) Novel method for the isolation and characterisation of the putative prostatic stem cell. Cytometry A 54: 89-99.
21. Cortes-Dericks L, Carboni GL, Schmid RA, Karoubi G, (2010) Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed. Int J Oncol 37: 437-44.
22. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL, (2008) CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 98: 756-65.
23. Liu T, Xu F, Du X, Lai D, Liu T, et al. (2010) Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1. Mol Cell Biochem 340: 265-73.
24. Forristal CE, Wright KL, Hanley NA, Oreffo RO, Houghton FD, (2010) Hypoxia inducible factors regulate pluripotency and proliferation in human embryonic stem cells cultured at reduced oxygen tensions. Reproduction 139: 85-97.
25. Ma T, Grayson WL, Frohlich M, Vunjak-Novakovic G, (2009) Hypoxia and stem cell-based engineering of mesenchymal tissues. Biotechnol Prog 25: 32-42.
26. Kim Y, Lin Q, Glazer PM, Yun Z, (2009) Hypoxic tumor microenvironment and cancer cell differentiation. Curr Mol Med 9: 425-34.
27. Kim Y, Lin Q, Zelterman D, Yun Z, (2009) Hypoxia-regulated delta-like 1 homologue enhances cancer cell stemness and tumorigenicity. Cancer Res 69: 9271-80.
28. Malladi P, Xu Y, Chiou M, Giaccia AJ, Longaker MT, (2007) Hypoxia inducible factor-1alpha deficiency affects chondrogenesis of adipose-derived adult stromal cells. Tissue Eng 13: 1159-71.
29. Jeter CR, Liu B, Liu X, Chen X, Liu C, et al. (2011) NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene 30: 3833-45.
30. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, et al. (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17: 1253-70.
31. Kim JH, Jee MK, Lee SY, Han TH, Kim BS, et al. (2009) Regulation of adipose tissue stromal cells behaviors by endogenic Oct4 expression control. PLoS One 4: e7166.
32. Yasuda SY, Tsuneyoshi N, Sumi T, Hasegawa K, Tada T, et al. (2006) NANOG maintains self-renewal of primate ES cells in the absence of a feeder layer. Genes Cells 11: 1115-23.
33. Pascal LE, Oudes AJ, Petersen TW, Goo YA, Walashek LS, et al. (2007) Molecular and cellular characterization of ABCG2 in the prostate. BMC Urol 7: 6.
34. Mori R, Dorff TB, Xiong S, Tarabolous CJ, Ye W, et al. (2010) The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes. Prostate 70: 1692-700.
35. Khandrika L, Lieberman R, Koul S, Kumar B, Maroni P, et al. (2009) Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1alpha levels contribute to emergence of an aggressive phenotype in prostate cancer. Oncogene 28: 1248-60.
36. Koh MY, Powis G, (2009) HAF: the new player in oxygen-independent HIF-1alpha degradation. Cell Cycle 8: 1359-66.
37. Kimbro KS, Simons JW, (2006) Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 13: 739-49.
38. Park JY, Park JW, Suh SI, Baek WK, (2009) D-glucosamine down-regulates HIF-1alpha through inhibition of protein translation in DU145 prostate cancer cells. Biochem Biophys Res Commun 382: 96-101.
39. Bryant CS, Munkarah AR, Kumar S, Batchu RB, Shah JP, et al. (2010) Reduction of hypoxia-induced angiogenesis in ovarian cancer cells by inhibition of HIF-1 alpha gene expression. Arch Gynecol Obstet 282: 677-83.
40. Hua K, Din J, Cao Q, Feng W, Zhang Y, et al. (2009) Estrogen and progestin regulate HIF-1alpha expression in ovarian cancer cell lines via the activation of Akt signaling transduction pathway. Oncol Rep 21: 893-8.
41. Shin J, Lee HJ, Jung DB, Jung JH, Lee HJ, et al. (2011) Suppression of STAT3 and HIF-1 Alpha Mediates Anti-Angiogenic Activity of Betulinic Acid in Hypoxic PC-3 Prostate Cancer Cells. PLoS One 6: e21492.
42. Monsef N, Helczynski L, Lundwall A, Pahlman S, (2007) Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands. Prostate 67: 1219-29.
43. Li Z, Rich JN, (2010) Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr Top Microbiol Immunol 345: 21-30.
44. Mathews LA, Hurt EM, Zhang X, Farrar WL, (2010) Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells. Mol Cancer 9: 267.
45. Covello KL, Kehler J, Yu H, Gordan JD, Arsham AM, et al. (2006) HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 20: 557-70.
46. Li H, Chen X, Calhoun-Davis T, Claypool K, Tang DG, (2008) PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res 68: 1820-5.
47. Oates JE, Grey BR, Addla SK, Samuel JD, Hart CA, et al. (2009) Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers. Stem Cells Dev 18: 1515-22.
48. Marsden CG, Wright MJ, Pochampally R, Rowan BG, (2009) Breast tumor-initiating cells isolated from patient core biopsies for study of hormone action. Methods Mol Biol 590: 363-75.
49. Ponti D, Zaffaroni N, Capelli C, Daidone MG, (2006) Breast cancer stem cells: an overview. Eur J Cancer 42: 1219-24.
50. Arai F, Suda T, (2007) Maintenance of quiescent hematopoietic stem cells in the osteoblastic niche. Ann N Y Acad Sci 1106: 41-53.
51. Ishimoto T, Oshima H, Oshima M, Kai K, Torii R, et al. (2010) CD44+ slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis. Cancer Sci 101: 673-8.
52. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, et al. (2004) The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 279: 24218-25.
53. Mohan A, Kandalam M, Ramkumar HL, Gopal L, Krishnakumar S, (2006) Stem cell markers: ABCG2 and MCM2 expression in retinoblastoma. Br J Ophthalmol 90: 889-93.
54. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, et al. (2006) Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25: 1696-708.
55. Hong SP, Wen J, Bang S, Park S, Song SY, (2009) CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 125: 2323-31.
56. Lukacs RU, Lawson DA, Xin L, Zong Y, Garraway I, et al. (2008) Epithelial stem cells of the prostate and their role in cancer progression. Cold Spring Harb Symp Quant Biol 73: 491-502.